Skip Navigation


Brain Advance Access originally published online on July 10, 2007
Brain 2007 130(8):2004-2010; doi:10.1093/brain/awm144
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
130/8/2004    most recent
awm144v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Piepers, S.
Right arrow Articles by Van den Berg, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piepers, S.
Right arrow Articles by Van den Berg, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial

Sanne Piepers, Renske Van den Berg-Vos, W-Ludo Van der Pol, Hessel Franssen, John Wokke and Leonard Van den Berg

Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, the Netherlands

Correspondence to: Dr Renske M. Van den Berg-Vos, MD, PhD, Department of Neurology, Rudolf Magnus Institute of Neuroscience, PO Box 85500 3508 GA Utrecht, the Netherlands E-mail: r.vandenberg-vos{at}slaz.nl

Multifocal motor neuropathy (MMN) is an immune-mediated disorder characterized by slowly progressive asymmetrical limb weakness. Treatment with immunoglobulins (IVIg) leads to improvement of muscle strength. Anecdotal evidence suggests that immunosuppressive drugs as adjunctive therapy may be beneficial. Mycophenolate mofetil (MMF) is a potent and safe immunosuppressant. Safety and efficacy of MMF as adjunctive therapy for MMN patients receiving IVIg maintenance treatment were evaluated in a randomized controlled trial. MMN patients responding to IVIg treatment were eligible for randomization. Muscle strength and functional status were assessed at monthly intervals for 1 year. Three months after the start of MMF or placebo treatment, IVIg doses were reduced stepwise, until a deterioration of functioning or decline in muscle strength could be observed. An IVIg dose reduction of 50% during adjunctive treatment was defined as a primary endpoint. Secondary outcome measures were improvement in muscle strength and functional status after 3 months and reduction of anti GM1-IgM titres after 12 months of MMF treatment. Twenty-eight patients were randomized. One patient allocated to MMF reached the primary endpoint of 50% IVIg dose reduction. After 12 months IVIg reduction did not differ significantly between the two treatment groups. Patients did not experience drug toxicity and none of the patients showed significant disease progression after 12 months. Muscle strength and functional scores after 3 months and anti GM1-IgM titres after 12 months did not change. Adjunctive treatment of MMN patients with MMF at a dose of 1 g twice daily is safe but does not alter disease course or allow significant reduction of IVIg doses.

Key Words: multifocal motor neuropathy; immune-mediated neuropathy; immunosuppressant; treatment; immunoglobulins

Abbreviations: MMN, multifocal motor neuropathy; IVIg, intravenous human immunoglobulins; MMF, mycophenolate mofetil; MMT, manual muscle testing; MRC, Muscle Research Council; SES, self-evaluation scale; ELISA, enzyme-linked immunosorbent assay; SAE, Serious adverse events

Received February 28, 2007. Revised May 11, 2007. Accepted May 29, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
Y A Rajabally
Multifocal motor neuropathy: review of a treatable immune mediated disorder
Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.